Biomerica (NASDAQ: BMRA) director adds shares in $1.60 private placement
Rhea-AI Filing Summary
BIOMERICA INC (BMRA) director David Moatazedi reported purchasing common stock in a company financing. On August 26, 2026, he acquired 10,000 shares of Biomerica common stock at $1.60 per share in a private placement by Biomerica under a Securities Purchase Agreement dated August 20, 2026. Following this transaction, he directly holds 40,625 shares of Biomerica common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 10,000 shares
Net Buy
1 txn
Insider
MOATAZEDI DAVID
Role
Director
Bought
10,000 shs ($16K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common stock F1 | 10,000 | $1.60 | $16K |
Holdings After Transaction:
Common stock — 40,625 shares (Direct)
Footnotes (1)
- F1. On August 26, 2026, the reporting person acquired 10,000 shares of the Issuer's common stock at a purchase price of $1.60 per share in private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated August 20, 2026, by and among certain institutional and individual investors identified on the signature pages thereto, which included among others B. Riley Principal Capital, LLC and certain members of the Company's Board of Directors and executive officers.
Key Figures
Shares purchased: 10,000 shares of common stock
Purchase price per share: $1.60 per share
Shares owned after transaction: 40,625 shares of common stock
+2 more
5 metrics
Shares purchased
10,000 shares of common stock
Acquired on August 26, 2026 in private placement by Biomerica
Purchase price per share
$1.60 per share
Price paid for BMRA common stock in the August 26, 2026 transaction
Shares owned after transaction
40,625 shares of common stock
Direct holdings of David Moatazedi following the reported purchase
Transaction date
August 26, 2026
Date of the reported common stock purchase in the Form 4
Agreement date
August 20, 2026
Date of the Securities Purchase Agreement governing the private placement
Key Terms
private placement, Securities Purchase Agreement, institutional investors, beneficial ownership
4 terms
private placement financial
"acquired 10,000 shares of the Issuer's common stock at a purchase price of $1.60 per share in private placement by the Issuer"
A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.
Securities Purchase Agreement financial
"pursuant to the terms of a Securities Purchase Agreement dated August 20, 2026"
A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.
institutional investors financial
"by and among certain institutional and individual investors identified on the signature pages"
Institutional investors are large organizations, like pension funds, insurance companies, and mutual funds, that invest huge amounts of money on behalf of many people. Their decisions can influence the economy because they buy and sell big chunks of stocks, bonds, or other assets. They matter because their actions can affect market prices and trends.
beneficial ownership financial
"the reporting person acquired 10,000 shares of the Issuer's common stock"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
FAQ
What insider transaction did BMRA director David Moatazedi report?
David Moatazedi reported a purchase of 10,000 BMRA common shares on August 26, 2026 at $1.60 per share in a private placement by Biomerica. After this transaction, he directly holds 40,625 shares of Biomerica common stock.
Was the BMRA insider purchase by David Moatazedi part of a private placement?
Yes. The filing states that on August 26, 2026, David Moatazedi acquired 10,000 BMRA shares at $1.60 per share in a private placement by Biomerica pursuant to a Securities Purchase Agreement dated August 20, 2026.
Which other investors were involved in the BMRA private placement mentioned in this Form 4?
The Securities Purchase Agreement dated August 20, 2026 lists certain institutional and individual investors, including B. Riley Principal Capital, LLC and certain members of Biomerica’s Board of Directors and executive officers, along with other investors identified on the signature pages.
AI-generated analysis. How Rhea-AI works. Not financial advice.
